398 results about "Transforming growth factor" patented technology

Provided are a method for inducing the transdifferentiation of somatic cells into neural stem cells and application for same. Using a combination of a histone deacetylase (HDAC) inhibitor, a glycogen synthase kinase (GSK-3) inhibitor, and a transforming growth factor β (TGF-β) signal pathway inhibitor, in a low-oxygen normal physiological environment, induce somatic cells such as fibroblasts and epithelial cells to form into neural stem cells having good pluripotency and passage stability.

Methods and devices are described for the regulation of Transforming Growth actor (TGF)-β1, β2, and / or β3 protein gene expression in bone cells and other tissues via the capacitive coupling or inductive coupling of specific and selective electric fields to the bone cells or other tissues, where the specific and selective electric fields are generated by application of specific and selective electric and electromagnetic signals to electrodes or one or more coils or other field generating device disposed with respect to the bone cells or other tissues so as to facilitate the treatment of diseased or injured bone and other tissues. By gene expression is meant the up-regulation or down-regulation of the process whereby specific portions (genes) of the human genome (DNA) are transcribed into mRNA and subsequently translated into protein. Methods and devices are provided for the targeted treatment of injured or diseased bone and other tissue that include generating specific and selective electric and electromagnetic signals that generate fields in the target tissue optimized for increase of TGF-β1, β2, and / or β3 protein gene expression and exposing bone and other tissue to the fields generated by specific and selective signals so as to regulate TGF-β1, β2, and / or β3 protein gene expression in such tissue. The resulting methods and devices are useful for the targeted treatment of bone fractures, fractures at risk, delayed unions, nonunion of fractures, bone defects, spine fusions, osteonecrosis or avascular necrosis, as an adjunct to other therapies in the treatment of one or all of the above, in the treatment of osteoporosis, and in other conditions in which TGF-β1, β2, and / or β3 protein may be implicated.

The present invention relates to a folding process for the preparation of biologically active, dimeric TGF- beta (Tranforming Growth Factor type beta )-like protein.

Antisense compounds, compositions and methods are provided for modulating the expression of transforming growth factor-beta 3. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding transforming growth factor-beta 3. Methods of using these compounds for modulation of transforming growth factor-beta 3 expression and for treatment of diseases associated with expression of transforming growth factor-beta 3 are provided.

The present invention relates to a folding process for the preparation of biologically active, dimeric, TGF-β (Transforming Growth Factor type β)-like protein in a detergent-free folding buffer.

The short form version of c-Maf transcription factor is up-regulated in steroid-treated and transforming growth factor beta2-treated trabecular meshwork cells, and is present at elevated levels in glaucomatous versus normal trabecular meshwork cells and in glaucomatous versus normal optic nerve head tissue. Expression of short form c-Maf transcription factor under these conditions indicates a causal or effector role for the factor in primary open-angle and steroid-induced glaucoma pathogenesis. Antagonism of short form c-Maf transcription factor expression and / or activity in the trabecular meshwork or other ocular tissue is provided for inhibiting or alleviating glaucoma pathogenesis. Antagonists include cyclin-dependent kinase 2 inhibitors.

The invention provides a serum-free adipose-derived stem cell culture medium, belonging to the technical field of stem cells. The serum-free adipose-derived stem cell culture medium comprises an IMDM (Iscove's modified Dulbecco's medium) basal culture medium, recombinant human insulin, recombinant transferrin, vitamin C, human serum albumin, fibroblast growth factor, platelet-derived growth factor, epidermal growth factor, insuline-like growth factor, transforming growth factor, fiber connexin, fetuin, tea polyphenol and stem cell growth factor. The serum-free adipose-derived stem cell culture medium provided by the invention does not need to perform culture bottle coating, and has the advantages of cell adherent property, favorable morphology and high cell proliferation rate.

This invention relates to 2-pyridyl substituted imidazoles which are inhibitors of the transforming growth factor-β (TGF-β) type I receptor (ALK5) and / or the activin type I receptor (ALK4), methods for their preparation, and their use in medicine, specifically in the treatment and prevention of a disease state mediated by these receptors.

The present invention is directed to a method of making a stable composition comprising growth factors, which may include platelet derived growth factors and transforming growth factors. The method comprises providing human umbilical cord blood plasma containing platelets, but substantially free of whole blood cells, and lysing the platelets to extrude growth factors into the plasma. The plasma may be obtained from multiple donors and pooled to form a homologous plasma mixture. In another embodiment, the growth factors are encapsulated in a liposome formed by a lipid bilayer, wherein the resulting composition remains stable and viable for at least 30 months. The present invention is also directed to the composition produced by the methods of the present invention and the process of applying the composition to a skin defect or wound.

The present disclosure relates to methods of regenerating cartilage. In an embodiment, a method includes initiating a release of precursor cells, including bone marrow cells and progenitor cells, into a cartilage defect; and applying a population of exogenous cells to the cartilage defect. The exogenous cells, selected from a group including chondrocytes, synoviocytes, fat pad cells, chondroprogenitor cells, mesenchymal stem cells, and any combination thereof, induce the precursor cells to form cartilage tissue through a release of factors by the exogenous cells. The factors stimulate the precursor cells to form cartilage cells. The cartilage cells then form cartilage tissue. The factors are selected from a group including transforming growth factors, fibroblast growth factors, platelet-derived growth factors, insulin-like growth factors, epidermal growth factors, interleukins, and any combination thereof. Other methods of regenerating cartilage are also disclosed.

The invention provides methods, compositions, and kits for treating a variety of conditions using substances that display one or more activities of transforming growth factor-β (TGF-β mimics). Conditions include skin conditions, wounds, and the need for soft tissue augmentation. Compositions that may be used to treat such conditions contain a TGF-β mimic. Kits that may be used to treat such conditions contain a TGF-β mimic.

Gene expression profiling and hierarchial clustering analysis readily distinguish normal ovarian epithelial cells from primary ovarian serous papillary carcinomas. Laminin, tumor-associated calcium signal transducer 1 and 2 (TROP-1 / Ep-CAM; TROP-2), claudin 3, claudin 4, ladinin 1, S100A2, SERPIN2 (PAI-2), CD24, lipocalin 2, osteopontin, kallikrein 6 (protease M), kallikrein 10, matriptase and stratifin were found among the most highly overexpressed genes in ovarian serous papillary carcinomas, whereas transforming growth factor beta receptor III, platelet-derived growth factor receptor alpha, SEMACAP3, ras homolog gene family, member I (ARHI), thrombospondin 2 and disabled-2 / differentially expressed in ovarian carcinoma 2 (Dab2 / DOC2) were significantly down-regulated. Therapeutic strategy targeting TROP-1 / Ep-CAM by monoclonal chimeric / humanized antibodies may be beneficial in patients harboring chemotherapy-resistant ovarian serous papillary carcinomas.

The invention discloses a preparation method of a functional hydrogel medical dressing. The preparation method comprises the following steps: 1. blending a biopolymer material, a chemical synthesized polymer material, a transforming growth factor TGF-beta and distilled water so as to form a physical-crosslinked hydrogel, wherein the biopolymer material consists of carboxymethyl chitosan, chitosan quaternary ammonium salt, gelatin, gellan gum and sodium alginate; and the chemical synthesized polymer material consists of polyvinyl alcohol and polyvinylpyrrolidone; 2. coating and processing the physical-crosslinked hydrogel obtained in the step 1 by virtue of a coating machine; and 3. conducting radiation sterilization on the hydrogel which is coated in the step 2, and implementing radiation crosslinking during the process of radiation sterilization. The method, through physical crosslinking and radiation crosslinking, can form the hydrogen of a dual-network structure; and the hydrogel medical dressing is high in strength and melting-up property, and the dressing is capable of protecting wound surfaces, stopping bleeding, relieving pain, inhibiting bacteria and promoting the growth of epithelial cell.

An artificial tooth root material with induced osteoplastic bioactivity is prepared through spraying a gradient bioactive layer on the surface of the metallic basic material which has excellent biologic compatibility and combining the bone morphogenetic protein, alkaline fibroblast growth factor, or conversion growth factor onto the surface of said coated layer. Said coated layer contains hydroxyphosphorite nano-powder, bioactive glass nanopowder, alumina nano powder and titanium oxide nano powder. Its advantages are high bioactivity and high adhesion of coated layer.

The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.

The invention provides a serum-free culture medium for umbilical cord mesenchymal stem cells. The serum-free culture medium is characterized by comprising a DMEM low-sugar culture medium, transferrin, serum albumin, insulin, platelet-derived growth factors, epidermal growth factors, transforming growth factors, beta-mercaptoethanol, dihydromyricetin and catechin. The invention belongs to the technical field of stem cell culture. The serum-free culture medium for umbilical cord mesenchymal stem cells, provided by the invention, can obviously promote the adherence performance and multiplication rate of the umbilical cord mesenchymal stem cells, is beneficial to the multiplication of the umbilical cord mesenchymal stem cells and the maintenance of features of the stem cells, is excellent in adipogenesis and osteogenic induction differentiation potential, is relatively simple in component of the culture medium and is relatively low in cost.

The invention discloses a skin-care, defect-repairing, anti-aging and winkle-removing cosmetic preparation. A recombinant human platelet-derived growth factor (rhPDGF) which contains bioactive constituents and has a dermis repairing function, other growth factors such as a transforming growth factor (TGF-beta), an acidic fibroblast growth factor (aFGF), a basic fibroblast growth factor (bFGF) and an epidermal growth factor (EGF), and a hyaluronic acid (HA) compound preparation are introduced into the dermis by a daily skin care or cosmetic introducing method to stimulate the growth and the mitosis of fibroblasts in the dermis, the synthesis and the secretion of collagen and the HA and the growth and repair of collagenous fiber and elastic fiber so as to repair skin tissue defects such as skin depression, deep wrinkle, fracture of dermis fibrous tissue and the like caused by aging or skin damage. Therefore, skin beautifying and anti-aging effects are achieved.

The invention relates to a biological preparation for promoting quick growth and repair of a skin tissue. The preparation comprises the components in parts by weight as follows: 20-50 parts of active growth factor group and nutritional components and 1 part of biological general flavone, wherein the active growth factor group and nutritional components comprise epidermal growth factors (EGF), nerve growth factors (NGF), vascular endothelial growth factors (VEGF), stem cell growth factors (SCF), hepatocyte growth factors (HGF), transforming growth factors (TGF), fibroblast growth factors (bFGF), collagen, hyaluronic acids, polypeptide, nucleic acids and amino acids; the source for extracting the active growth factor group and nutritional components is original stem cells separated from cord blood or umbilical cord or placenta of new-born; and the biological general flavone is extracted from natural Chinese herbal medicines. The preparation provided by the invention is a pure natural biological preparation and can promote quick growth and repair of the skin tissue.

The invention provides a serum-free human amniotic mesenchymal stem cell culture medium, and belongs to the technical field of stem cells. The serum-free human amniotic mesenchymal stem cell culture medium comprises the following components: an IMDM basal culture medium, recombinant human insulin, recombinant transferrin, vitamin C, human serum albumin, fibroblast growth factors, platelet-derived growth factors, epidermal growth factors, insulin-like growth factors, transforming growth factors, fibronectin, fetuin, putrescine salt and recombinant human activin. The serum-free human amniotic mesenchymal stem cell culture medium provided by the invention does not need a culture bottle coating process, and is good in cell adherence and morphology and high in cell proliferation rate.